Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yassar M Hashim

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Journal of Experimental & Clinical Cancer Research : CR|January 19, 2017
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancerYassar M Hashim, Suwanna Vangveravong, Narendra V Sankpal, et al.
BMC Cancer|March 13, 2022
The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancerPratibha S Binder, Yassar M Hashim, James Cripe, et al.
Oncotarget|June 1, 2016
Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeuticKerri A Ohman, Yassar M Hashim, Suwanna Vangveravong, et al.
Trauma Surgery & Acute Care Open|November 29, 2023
Rates and risk factors for anastomotic leak following blunt trauma-associated bucket handle intestinal injuries: a multicenter studyHolly Grossman, Chathurka Samudani Dhanasekara, Kripa Shrestha, et al.
Annals of Surgery|August 14, 2014
Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patientsDavid A Kooby, Neha L Lad, Malcolm H Squires, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Journal of Experimental & Clinical Cancer Research : CR|January 19, 2017
The Targeted SMAC Mimetic SW IV-134 is a strong enhancer of standard chemotherapy in pancreatic cancerYassar M Hashim, Suwanna Vangveravong, Narendra V Sankpal, et al.
BMC Cancer|March 13, 2022
The targeted SMAC mimetic SW IV-134 augments platinum-based chemotherapy in pre-clinical models of ovarian cancerPratibha S Binder, Yassar M Hashim, James Cripe, et al.
Oncotarget|June 1, 2016
Conjugation to the sigma-2 ligand SV119 overcomes uptake blockade and converts dm-Erastin into a potent pancreatic cancer therapeuticKerri A Ohman, Yassar M Hashim, Suwanna Vangveravong, et al.
Trauma Surgery & Acute Care Open|November 29, 2023
Rates and risk factors for anastomotic leak following blunt trauma-associated bucket handle intestinal injuries: a multicenter studyHolly Grossman, Chathurka Samudani Dhanasekara, Kripa Shrestha, et al.
Annals of Surgery|August 14, 2014
Value of intraoperative neck margin analysis during Whipple for pancreatic adenocarcinoma: a multicenter analysis of 1399 patientsDavid A Kooby, Neha L Lad, Malcolm H Squires, et al.
Pageof 2